Oleolive Inc was awarded funding from the National Heart, Lung, and Blood Institute to study a repurposed drug to treat lung fibrosis.

Pulmonary fibrosis, including idiopathic pulmonary fibrosis, is a condition with severe morbidity, high mortality rates, and few therapeutic options for patients. Oleolive has identified an FDA approved drug that suppresses fibrosis in in vitro and in vivo models and warrants further development to allow repurposing for pulmonary fibrosis patients. To improve efficacy and increase safety OL-JC1 is being developed as an inhalation agent.